Intuitive Surgical shares fall as insurance changes cloud U.S. procedure demand

Traders Union
All News
Financial News
Intuitive shares fall on insurance

Highlights

Intuitive Surgical shares drop over 12% premarket after it maintains global procedure forecasts and warns insurance changes could hurt U.S. demand.
Second-quarter U.S. da Vinci procedure growth at 12% comes in below expectations, mainly in deferrable surgeries, attributed to coverage and premium dynamic changes.
Expiration of enhanced ACA premium subsidies modestly reduces U.S. procedure volumes, raising broader concerns about insurance-driven demand softness in the medtech sector.

Procedure outlook and coverage pressures

As reported by Reuters, Intuitive Surgical shares fall more than 12% before the bell on Friday after the company maintains its global forecast for procedures performed with its da Vinci surgical robots and warns that changes to some insurance plans could hurt demand.

The update disappoints Wall Street analysts, particularly after Abbott says it is a flawed assumption that Obamacare, or Affordable Care Act, enrollment declines are materially affecting the medical technology and diagnostics industry. Earlier this week, HCA Healthcare, the largest for-profit U.S. hospital operator, warns of softer demand for surgical procedures and a growing number of uninsured patients as many Americans drop ACA plans after pandemic-era subsidies expire.

Intuitive expects 2026 worldwide da Vinci-assisted procedure growth to come in near the midpoint of its 13.5% to 15.5% forecast range. Second-quarter da Vinci procedure growth in the U.S. is 12%, below the company's expectations at the start of the year, mainly in surgeries that can be deferred.

Medtech sector impact and analyst response

Chief Executive David Rosa says on a call on Thursday that some customers report changes in patient coverage and premium dynamics may be affecting when patients seek care and proceed with treatment. Intuitive says the expiration of enhanced ACA premium subsidies has a modest adverse impact on second-quarter U.S. da Vinci procedure growth.

Evercore ISI analyst Vijay Kumar says the softness in Intuitive's U.S. procedures, the slowest in three years, rekindles the debate over how much insurance changes are weighing on demand. J.P. Morgan analyst Robbie Marcus says procedures are central to the company's downstream revenue story, and that management is not yet able to quantify the effect of expired ACA subsidies, though his sense is that the impact is small in percentage terms.

In our earlier article on GSK’s stock slide after it discontinued camlipixant for refractory chronic cough, we explained how disappointing Phase III results can abruptly undermine market confidence. We also noted that insider reinvestment and ongoing pipeline activity did little to offset the bearish technical setup, leaving the shares under pressure and traders focused on key support and resistance levels.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.